**Supplemental table 1.** Prevalence and extent of coronary plaque according to ever use of specific antiretroviral drugs

|  |  |
| --- | --- |
|  | **Drug or drug class\*** |
|  | **abacavir** | **stavudine** | **zidovudine** | **PIs** | **atazanavir** | **darunavir** | **lopinavir** | **ritonavir** | **Overall** |
| **Non-contrast coronary CT scans, n** | 270 | 340 | 437 | 479 | 192 | 90 | 186 | 369 | 618 |
| Prevalence of CAC¥  | 148(54.8) | 187(55) | 236(54) | 255(53.2) | 99(51.6) | 56(62.2) | 94(50.5) | 194(52.6) | 328(53.1) |
| **Contrast coronary CT scan, n** | 174 | 237 | 311 | 344 | 135 | 61 | 129 | 261 | 450 |
|  Prevalence of any plaque | 138(79.3) | 185(78.1) | 254(81.7) | 270(78.5) | 107(79.3) | 46(75.4) | 100(77.5) | 206(78.9) | 349(77.6) |
|  Prevalence of calcified plaque | 58(33.3) | 82(34.6) | 116(37.3) | 122(35.5) | 49(36.3) | 20(32.8) | 44(34.1) | 87(33.3) | 156(34.7) |
|  Prevalence of noncalcified plaque | 116(66.7) | 153(64.6) | 213(68.5) | 219(63.7) | 85(63) | 38(62.3) | 78(60.5) | 164(62.8) | 285(63.3) |
|  Prevalence of mixed plaque | 62(35.6) | 83(35) | 115(37) | 125(36.3) | 49(36.3) | 22(36.1) | 44(34.1) | 94(36) | 156(34.7) |
|  Prevalence of coronary stenosis  | 31(17.8) | 45(19) | 62(19.9) | 66(19.2) | 26(19.3) | 13(21.3) | 27(20.9) | 48(18.4) | 76(16.9) |
| **Extent of plaque\*\*, median (IQR)** |   |   |   |   |   |   |   |   |   |
| CAC score | 70(19-248) | 71(21-225) | 71(23-210) | 71(23-205) | 71(20-167) | 59(21-178) | 59(24-156) | 68(20-182) | 70(22-190) |
| Total plaque score | 4(2-7) | 4(2-7) | 4(2-7) | 4(2-7) | 4(2-6) | 4(2-7) | 4(2-7) | 4(2-6) | 4(2-7) |
| Calcified plaque score | 1(1-1) | 1(1-1) | 1(1-1) | 1(1-1) | 1(1-1) | 1(1-1) | 1(1-1) | 1(1-1) | 1(1-1) |
| Noncalcified plaque score | 2(1-4) | 2(1-4) | 2(1-4) | 2(1-4) | 2(1-4) | 2(1-4) | 2(1-4) | 2(1-4) | 2(1-4) |
| Mixed plaque score | 2(1-4) | 2(1-3) | 2(1-4) | 2(1-3) | 2(1-3) | 2(2-6) | 2(1-3) | 2(1-3) | 2(1-3) |

\*Includes all individuals that ever received the drug or drug class. These categories are not mutually exclusive. \*\*Among men with coronary plaque present; ¥Agatston score > 0; PIs = protease inhibitors; CAC = coronary artery calcium; IQR = interquartile range

**Supplemental table 2. HIV characteristics by zidovudine and darunavir use**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Characteristics, Median (IQR)** | **zidovudine experienced** | **zidovudine naïve** | ***P*** | **darunavir experienced** | **darunavir naïve** | ***P*** |
| Number of men | 437 | 181 |  | 90 | 528 |  |
| Duration of HIV infection (years) | 20.4(12.5-25.9) | 10.4(8.7-15.7) | <0.001 | 19.5(12.5-25.9) | 14.5(10-25.3) | 0.020 |
| CD4 count before HAART initiation(cells/mm3) | 308(187-461) | 374(242-544) | <0.001 | 283(129-423) | 340(216-505) | 0.013 |
| Duration of mono/dual ART prior to HAART (years) | 2.4(0-8) | 0(0-1.8) | <0.001 | 4.5(0-9) | 0.3(0-7.5) | 0.011 |
| Percent of visits with detectable HIV RNA\* | 24(6-50) | 13(0-50) | 0.016 | 48(20-65) | 20(4-47) | <0.001 |

\*HIV RNA > 50 copies/mm3